FDA schedules public hearing on CSPI petition to revoke GRAS status for salt
About 18 months ago the Center for Science in the Public Interest (CSPI) petitioned to rescind FDA's Generally Recognized as Safe (GRAS regulatory exemption), arguing that since salt was implicated in hypertension, it wasn't "safe" and should be regulated as other food ingredients. FDA was obligated to conduct a public meeting, though it delayed considerably in scheduling. Repeal of GRAS would subject salt to FDA regulatory limits -- the authority to have food manufacturers limit the amount of salt in their products.
The public hearing has been scheduled for November 29th. The Salt Institute will testify.
